Skip to content

Clinical trials

Scleroderma, Systemic trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Scleroderma, Systemic Phase: Not applicable Country / region: China Clear all

13 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20231
20244
20255
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting7
Not yet recruiting2
Unknown status2
Active, not recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Anhui Provincial Hospital2
Bioray Laboratories1
China Immunotech (Beijing) Biotechnology Co., Ltd.1
Cytori Therapeutics1
Institute of Hematology & Blood Diseases Hospital, China1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.1
Second Affiliated Hospital, Zhejiang University, School of Medicine1
Shanghai Changzheng Hospital1
The Affiliated Hospital of Xuzhou Medical University1
The First Affiliated Hospital of University of Science and Technology of China1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Scleroderma, Systemic13
Lupus Erythematosus, Systemic11
Antiphospholipid Syndrome5
Myositis5
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis4
Arthritis, Rheumatoid4
Sjogren's Syndrome4
Autoimmune Diseases3
Dermatomyositis1
Immunoglobulin G4-Related Disease1

Trials

Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.